Watch AUTL. Know when insiders buy.
One email the day a filing lands. Free.
Work order
75
PASS · insiders 49, shorts 100
Insiders, 90 days
−$16K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $596.2MP/E —DIV YIELD —FCF YIELD -39.04%REV TTM $117.4M +292.2%NET INCOME −$280.2MNET CASH $171.4M52W 1.21 – 2.54SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $45.7M | +118.4% | 55.2% | −$43.8M | −$39.1M | — | -0.15 | −$25.1M | $913K | −$26M | Aug 11 |
| Q1 2026 · Mar 31 | $26.2M | +191.9% | 6.3% | −$59.5M | −$71.6M | — | -0.27 | −$65.3M | $2.7M | −$68M | Aug 11 |
| Q4 2025 · Dec 31derived | $24.3M | +83655.2% | -4.3% | −$72.5M | −$90.3M | — | -0.34 | −$67.3M | −$885K | −$66.4M | Mar 27 |
| Q3 2025 · Sep 30 | $21.2M | — | -35.1% | −$71.6M | −$79.1M | — | -0.30 | −$67.9M | $4.4M | −$72.3M | Nov 12 |
| Q2 2025 · Jun 30 | $20.9M | — | -16.8% | −$61.2M | −$47.9M | — | -0.18 | −$72.8M | $7.3M | −$80.1M | Aug 11 |
| Q1 2025 · Mar 31 | $9M | −11.0% | -99.9% | −$65.2M | −$70.2M | — | -0.26 | −$75.6M | $8.2M | −$83.8M | Aug 11 |
| Q4 2024 · Dec 31derived | $29K | — | -39165.5% | −$75.9M | −$27.6M | — | -0.09 | −$37.9M | $11.1M | −$49M | Mar 27 |
| Q3 2024 · Sep 30 | $0 | — | — | −$67.9M | −$82.1M | — | -0.31 | −$76.7M | $9.6M | −$86.3M | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$58.9M | −$58.3M | — | -0.22 | −$51.1M | $841K | −$51.9M | Aug 12 |
| Q1 2024 · Mar 31 | $10.1M | — | 100.0% | −$38.8M | −$52.7M | — | -0.24 | −$40.5M | $533K | −$41M | Aug 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$53.3M | −$77.2M | — | -0.45 | −$24.8M | $1.5M | −$26.3M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$42.9M | −$45.8M | — | -0.26 | −$40.2M | $1.5M | −$41.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $75.4M | -27.8% | −$270.5M | −$287.5M | -381.4% | -1.08 | −$283.6M | $19M | −$302.6M | — | — |
| FY2024 · to Dec 31 | $10.1M | -12.5% | −$241.4M | −$220.7M | -2180.5% | -0.86 | −$206.3M | $22.1M | −$228.3M | — | — |
| FY2023 · to Dec 31 | $1.7M | 100.0% | −$179.7M | −$208.4M | -12272.3% | -1.20 | −$145.6M | $11M | −$156.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$143.4M | −$148.8M | — | -1.57 | −$112.3M | $10.8M | −$123.1M | — | — |
| FY2021 · to Dec 31 | — | — | −$141.1M | −$142.1M | — | -1.97 | −$117.9M | $8.9M | −$126.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$168.1M | −$142.1M | — | -2.76 | −$117.8M | $14.7M | −$132.4M | — | — |
Every number comes from Autolus Therapeutics plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.